<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

The Cancer Letter

Adding Avastin Did Not Improve Standard Chemotherapy Regimen

Ibrutinib Demonstrates Responses In Large B-Cell Lymphomas

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

Perifosine Fails Primary Endpoint, Zentaris CEO Explores Options

Translplants Not Best Choice in Subset of ALL Patients

PET Response Can Predict Increased Survival In Patients

Cancer Incidence Rates Climb In HIV-Positive Female Populations

Technology Isolates and Recovers Circulating Liver Tumor Cells

Survey Shows That One-Third Of Patients Are Undertreated

Trials Approved by NCI CTEP For the Month of April